Cancer Diagnostics Market is Expected to be Worth US$168,649.3 Million by 2020, Driven by Increasing Number of Lung Cancer Cases: Transparency Market Research

Dec 17, 2015, 03:30 ET from Transparency Market Research

ALBANY, New York, December 17, 2015 /PRNewswire/ --

Transparency Market Research (TMR) has announced the publication of a new report, titled "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020". According to this report, the global cancer diagnostics market is expected to grow at a CAGR of 7.6% during the forecast period of 2014 to 2020. In 2013, the global cancer diagnostics market was valued at US$100,994.5 million and is expected to be worth US$168,649.3 million by 2020.The increasing prevalence of cancer is the primary factor driving the global cancer diagnostics market. According to the WHO, the number of new cancer cases is projected to grow by approximately 70% in the next two decades. The rapidly growing number of cancer cases will fuel the growth of several sectors related to cancer diagnostics. According to method, the global cancer diagnostics market is divided into tumor biomarker tests, endoscopy, imaging, and biopsy. The segment of cancer imaging diagnosis is anticipated to grow at a CAGR of 8.2% during the forecasting horizon.

Browse Full Report Cancer Diagnostics Market (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 Research Report With Full TOC @

Imaging for cancer diagnosis has taken center stage in worldwide efforts aimed at cancer detection and prevention. Advanced diagnostics methods have achieved a reduction of 30% in mortality due to breast cancer. Hence, the imaging sector in the global cancer diagnostics market will continue its dominance in the foreseeable future.Application-wise, the global cancer diagnostics market is segmented into blood cancer, kidney cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic cancer, ovarian cancer, lung cancer, and liver cancer. The global cancer diagnostics market is mostly driven by the growing demand for lung cancer, breast cancer, and colorectal cancer diagnosis. The lung cancer segment is leading the market, as it is the most common type of cancer.

Get Sample Report Copy of Cancer Diagnostics Market:

Approximately 1.8 billion new cases of lung cancer were diagnosed in 2012.Geographically, the global cancer diagnostics market is segmented into North America, Asia Pacific, Europe, and Rest of the World (RoW). North America is the leading region in the global cancer diagnostics market. This regional market held a market share of 40.7% in the 2013 global cancer diagnostics market. The next region in the global cancer diagnostics market's regional hierarchy is Europe, which held a 29.1% share in the global cancer diagnostics market in 2013.Asia Pacific will grow at the fastest CAGR of 8.2%, while North America will register a growth at a 7.0% CAGR during the forecasting horizon. The Asia Pacific cancer diagnostics market is driven by the increasing prevalence of breast cancer in this region. The RoW market for cancer diagnostics will also register good growth in the foreseeable future due to the increasing incidence of lung cancer.

It is easier to receive regulatory approval for in-vitro cancer diagnostics in Europe as compared to the U.S., hence many companies are launching their products in Europe. Market players in the global cancer diagnostics market offer molecular diagnostic products, in-vitro diagnostic products, and imaging platforms. The top imaging equipment manufacturers are Siemens, GE Healthcare, and Philips Healthcare. The key vendors of oncology diagnostics tests and related products include Abbott Diagnostics, Roche, Myriad Genetics, Ambry Genetics, AstraZeneca, Eli Lily Company, and Pfizer.

Browse Press Release of Cancer Diagnostics Market:

Companies mentioned in the research report

The dominant players in the market profiled in the report include Ambry Genetics, Abbott Laboratories, Novartis, bioMerieux, GlaxoSmithKline plc, Roche, AstraZeneca, Pfizer, and Eli Lilly and Co.

Cancer Diagnostics Market, by Method:

  • Biopsy
  • Endoscopy
  • Tumor Biomarker Tests
  • Imaging

Major geographies analyzed under this research report are:

  • Europe
  • North America
  • Asia-Pacific
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Other Reports by Transparency Market Research:  

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr. Sudip.S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

SOURCE Transparency Market Research